N/A N=99 Randomized Treatment

A Trial of Telemonitoring in Adults With Heart Failure

Heart Failure

Bottom Line

View on ClinicalTrials.gov: NCT01393314 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Aug 2022

Primary outcome: Primary: The Amount of Time Participants Are Readmitted to the Hospital or Visit the Emergency Department (ED). — 60; 62 Days

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: Honeywell HomMed Telemonitor (Device)
Age: Adult, Older Adult · 55+ yrs
Sex: All
Sponsor: Case Western Reserve University
Primary completion: Mar 2010

Outcome Measures

Outcome	Result	p-value
PRIMARY The Amount of Time Participants Are Readmitted to the Hospital or Visit the Emergency Department (ED).	60; 62	—
SECONDARY Kansas City Cardiomyopathy Questionaire	34.3; 28.3	—

Summary

This is a randomized controlled trial of telemonitoring vs usual care provided by home care agencies for patients with heart failure. The study hypothesis is that Telemonitoring will reduce hospital re-admission rates, urgent care visits, unscheduled physician appointments, Emergency Room visits in patients with heart failure over the 60 day post hospitalization period.

Eligibility Criteria

Inclusion Criteria

Heart Failure (primary or secondary) diagnosis regardless of ejection fraction (EF) and New York Heart Association (NYHA) class II- IV at the time of Home Health Care (HHC) admission and HHC services initiated following a hospital stay

Exclusion Criteria

Inability to stand on a scale, weight over 500 pounds, unable to hear and/or see, or no working land line phone in the residence.
Additional exclusion criteria were: patients with severe ischemic heart disease, Myocardial Infarction (MI) and/or Coronary artery bypass graft surgery(CABG) in the last 6 weeks, severe uncorrected valvular disease, home inotropic therapy, severe lung disease (oxygen dependent), active cancer, uncorrected thyroid disease, AIDS, or end stage renal disease on dialysis.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01393314). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.